RUBICON1,791.00

Rubicon Research Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSHILPAMEDSPARCSTARSUPRIYAPARKHOSPSTHYROCAREMETROPOLISMARKSANSMcap ₹29,568 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations412.0475.5513.9534.3
Other Income0.73.82.65.7
Total Income412.7479.3516.5540.0
Expenses
+ Cost of Materials Consumed142.2183.6155.2153.9
+ Purchases of Stock-in-Trade21.221.845.022.1
+ Changes in Inventories-36.8-48.1-30.8-7.1
+ Employee Benefit Expense63.466.468.485.7
+ Finance Costs11.49.810.49.3
+ Depreciation & Amortisation11.911.612.315.1
+ Other Expenses127.8143.8157.6150.6
Total Expenses341.0388.7417.8429.6
EBITDA94.3108.1118.7129.1
EBIT82.496.6106.4114.0
Profit
PBT before Exceptional Items71.790.698.7110.4
Pretax Income71.790.698.7110.4
+ Current Tax21.217.732.431.6
+ Deferred Tax-3.30.1-10.5-6.0
Tax Expense17.917.821.925.6
Net Income53.972.876.884.8
+ Net Income — Continuing Ops53.972.876.884.8
+ Other Comprehensive Income-6.8-3.36.0-4.7
Total Comprehensive Income47.169.582.780.0
Net Income to Common53.972.876.884.8
Per Share
Basic EPS3.494.464.665.13
Diluted EPS3.474.414.605.08
Other Comprehensive Income — detail
+ Other Comprehensive Income-6.8-3.36.0-4.7
+ Items NOT to be Reclassified to P&L-0.5-0.1-0.00.1
+ Tax on Items NOT to be Reclassified-0.1-0.0-0.00.0
+ Items to be Reclassified to P&L-6.4-3.36.0-4.8
Comprehensive Income — Owners of Parent-6.8-3.382.780.0
Comprehensive Income — Non-controlling Interests47.169.50.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations3.494.464.665.13
Diluted EPS — Continuing Operations3.474.414.605.08
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit285.5318.3344.6365.4
Gross Margin %69.2866.9367.0668.38
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)71.790.698.7110.4
Net Income Adj (tax-effected)53.972.876.884.8
EPS Adj3.494.464.665.13
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital15.416.516.516.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.